Biotech and Pharma Industry News | BioPharma Dive
网页The withdrawal comes as trial results indicate safety concerns with the drug, Oxbryta, which was first approved in the U.S. in 2019. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. We cover topics like clinical trials, drug discovery and development, pharma marketing, FDA approvals and regulations, and more.
Drugmakers are racing to find the next Wegovy. These obesity …
网页1 天前 · Within the pharmaceutical industry, a multibillion-dollar race is underway to top Novo Nordisk’s and Eli Lilly’s in-demand obesity drugs. Dozens of companies, large and small, have set out to test experimental medicines they claim could be more potent, convenient or have fewer side effects than Novo’s Wegovy and Lilly’s Zepbound.
Deep Dive - BioPharma Dive
网页2024年6月27日 · A decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology. Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. Jonathan Gardner • Sept. 4 ...
A decade of cancer immunotherapy: Keytruda, Opdivo and the …
网页2024年9月4日 · Developed by Bristol Myers Squibb, Opdivo was the second so-called PD1 inhibitor to be approved in the U.S. The first, Merck & Co.’s Keytruda, won Food and Drug Administration clearance 10 years ago today. Keytruda’s initial U.S. approval, which preceded Opdivo’s by a few months, was niche, reserved for people with inoperable melanoma or whose disease had spread and couldn’t be ...
Biotech News - BioPharma Dive
网页2 天之前 · With $115M more, Triveni accelerates immune drug work. The biotech, which has now raised more than $200 million since launch, is advancing an eczema treatment that could start human trials next year. By Gwendolyn Wu • Oct. 2, 2024. Access now .
Upstream prices $255M IPO in bid to challenge Amgen, …
网页1 天前 · Upstream Bio announced Thursday it priced its initial public offering, raising $255 million to fund development of an antibody drug it’s testing against several respiratory diseases. The Waltham, Massachusetts-based biotechnology company sold 15 million shares at $17 apiece, exceeding the projections it set earlier this week.
10 clinical trials to watch in the second half of 2024
网页2024年7月1日 · Deep Dive. 10 clinical trials to watch in the second half of 2024. Study results are expected for a pair of closely watched obesity drugs, while key tests await for a high-priced AbbVie acquisition and one of 2023’s largest IPOs. Published July 1, 2024 • By BioPharma Dive staff.
Biotech stock fundings headed for best quarter in 3 years, Jefferies ...
网页2024年3月11日 · Data the firm published over the weekend show biotech is on pace to post its highest quarterly total in three years, potentially exceeding the $11 billion companies raised in follow-on stock offerings in the first quarter of 2021. The average size of those financings increased from $167 million in January to $191 million in February, the report ...
10 clinical trials to watch in the first half of 2023
网页2023年1月3日 · One of the most successful drug licensing deals in recent history came in 2019, when AstraZeneca agreed to pay Daiichi Sankyo as much as $6.9 billion for a piece of a cancer drug developed by the Japanese company. Since then, the drug, now sold as Enhertu for several tumor types, has become a mainstay in breast cancer care.Analysts expect it to generate more than $6 billion in yearly revenue ...
Biotech M&A has plateaued. Track the deals that are happening …
网页2024年10月4日 · BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to …